{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:33:19Z","timestamp":1786692799069,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003385","name":"Georg-August-Universit\u00e4t G\u00f6ttingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003385","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2i) are now widely applied in treatment plans for heart failure with reduced ejection fraction (HFrEF) patients, regardless of the presence of diabetes. SGLT2i, such as empagliflozin (EMP), reduce the risk of cardiovascular death and heart failure hospitalizations in HFrEF patients. However, the underlying molecular mechanisms of action, by which SGLT2i benefit cardiomyocytes (CMs) in HFrEF hearts, are not well understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study investigated the role of the SGLT2i, EMP, in a patient-specific human model of dilated cardiomyopathy (DCM), a primary cause of HFrEF, which is frequently caused by inherited mutations in sarcomere proteins. We employed DCM patient-specific induced pluripotent stem cell-derived CMs (iPSC-CMs) carrying the inherited sarcomere protein mutation tropomyosin (TPM1)-L185F together with high-speed motion traction and optical action potential mapping analysis, as well as biochemical methods to dissect molecular signaling dysfunctions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our findings indicate that in DCM patient-specific iPSC-CMs, SGLT2i may act via different mechanisms. This includes the regulation of signaling pathways, to modulate sarcomere function via improving mitochondrial respiration and ATP production. As our results show, the SGLT2i, EMP, ameliorates primary sarcomere dysfunctions in DCM TPM1-L185F iPSC-CMs, such as disrupted sarcomere organization, reduced contractile function, and prolonged action potential duration. Moreover, we found that a subcellular signaling pathway dysregulated in DCM CMs, clathrin-mediated endocytosis (CME)-dependent signaling, may be recovered by EMP treatment in DCM TPM1-L185F iPSC-CMs. This pathway is essential for the uptake and distribution of critical cargo, such as transferrin-bound Fe, in CMs. In the presence of the DCM-causing mutation, EMP recovered mitochondrial Fe levels and mitochondrial functional output, which are reduced in DCM iPSC-CMs as part of pathologically defective CME-dependent signaling. These findings support that EMP modulates aspects of CME-signaling, and contributes to restored sarcomere functions. To further elucidate the effects of SGLT2i in DCM CMs, we investigated the molecular functions of a state-of-the-art combinatorial therapy for DCM (HFrEF) patients, the drug combination referred to as \u201cfantastic four\u201d (F4), including an SGLT2i, in DCM iPSC-CMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our in-vitro results point to a significant benefit of F4 to be attributed to the SGLT2i, EMP, regarding sarcomere functions as well as aspects of CME-dependent recovery of molecular signaling. Moreover, studying the recovery of subcellular dysfunctions by EMP treatment, findings from an in-vivo porcine model of HF support improvements observed in the presence of EMP regarding contractile and electrophysiological parameters. Together, our findings provide molecular insights into the subcellular function of SGLT2i and their role as part of the F4 state-of-the-art combination therapy for HFrEF, via targeting different molecular signaling pathways in a human patient-specific 2D model of HFrEF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08702-0","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:14:46Z","timestamp":1785518086000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibition improves sarcomere contractile dysfunction in human models of dilated cardiomyopathy"],"prefix":"10.1186","volume":"24","author":[{"given":"Daria","family":"Plota","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza Nosheen","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruheen","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleophas","family":"Cheruiyot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"M\u00fcnzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabea","family":"Hutschenreiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Tiburcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Habeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram-Hubertus","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3642-242X","authenticated-orcid":false,"given":"Antje","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"8702_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2213-8587(21)00292-8","volume":"10","author":"S Verma","year":"2022","unstructured":"Verma S, et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol. 2022;10:35\u201345.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"8702_CR2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. JAMA. 2020;323:1353\u201368.","journal-title":"JAMA"},{"key":"8702_CR3","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1161\/CIRCULATIONAHA.120.053463","volume":"143","author":"J Jensen","year":"2021","unstructured":"Jensen J, et al. Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). Circulation. 2021;143:2208\u201310.","journal-title":"Circulation"},{"key":"8702_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","volume":"143","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. Circulation. 2021;143:337\u201349.","journal-title":"Circulation"},{"key":"8702_CR5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence. Int J Heart Fail. 2023;5:82\u201390.","journal-title":"Int J Heart Fail"},{"key":"8702_CR6","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.2147\/DDDT.S269514","volume":"14","author":"N Li","year":"2020","unstructured":"Li N, Zhou H. SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy. Drug Des Devel Ther. 2020;14:4775\u201388.","journal-title":"Drug Des Devel Ther"},{"key":"8702_CR7","doi-asserted-by":"publisher","first-page":"e09","DOI":"10.15420\/cfr.2023.25","volume":"10","author":"CN Nilsson","year":"2024","unstructured":"Nilsson CN, Ersboll MK, Gustafsson F. Haemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitor Treatment in Chronic Heart Failure Patients. Card Fail Rev. 2024;10:e09.","journal-title":"Card Fail Rev"},{"key":"8702_CR8","doi-asserted-by":"publisher","first-page":"e018298","DOI":"10.1161\/JAHA.120.018298","volume":"10","author":"X Li","year":"2021","unstructured":"Li X, et al. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure. J Am Heart Assoc. 2021;10:e018298.","journal-title":"J Am Heart Assoc"},{"key":"8702_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1093\/cvr\/cvae004","volume":"120","author":"PJM Wijnker","year":"2024","unstructured":"Wijnker PJM, et al. Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors. Cardiovasc Res. 2024;120:301\u201317.","journal-title":"Cardiovasc Res"},{"key":"8702_CR10","doi-asserted-by":"publisher","first-page":"8689","DOI":"10.1038\/s41598-023-35944-5","volume":"13","author":"D Silva Dos Santos","year":"2023","unstructured":"Silva Dos Santos D, et al. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1. Sci Rep. 2023;13:8689.","journal-title":"Sci Rep"},{"key":"8702_CR11","first-page":"2346","volume":"51","author":"S Yamanaka","year":"2006","unstructured":"Yamanaka S, Takahashi K. [Induction of pluripotent stem cells from mouse fibroblast cultures]. Tanpakushitsu Kakusan Koso. 2006;51:2346\u201351.","journal-title":"Tanpakushitsu Kakusan Koso"},{"key":"8702_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nmeth.1593","volume":"8","author":"G Chen","year":"2011","unstructured":"Chen G, et al. Chemically defined conditions for human iPSC derivation and culture. Nat Methods. 2011;8:424\u20139.","journal-title":"Nat Methods"},{"key":"8702_CR13","doi-asserted-by":"publisher","first-page":"130ra147","DOI":"10.1126\/scitranslmed.3003552","volume":"4","author":"N Sun","year":"2012","unstructured":"Sun N, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med. 2012;4:130ra147.","journal-title":"Sci Transl Med"},{"key":"8702_CR14","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1126\/science.aaa5458","volume":"349","author":"JT Hinson","year":"2015","unstructured":"Hinson JT, HEART DISEASE, et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science. 2015;349:982\u20136.","journal-title":"Science"},{"key":"8702_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41598-019-56597-3","volume":"10","author":"Y Dai","year":"2020","unstructured":"Dai Y, et al. Troponin destabilization impairs sarcomere-cytoskeleton interactions in iPSC-derived cardiomyocytes from dilated cardiomyopathy patients. Sci Rep. 2020;10:209.","journal-title":"Sci Rep"},{"key":"8702_CR16","doi-asserted-by":"crossref","unstructured":"Malkovskiy AV, et al. Integrated Ca2+ flux and AFM force analysis in human iPSC-derived cardiomyocytes. Biol Chem. 2020;402\u200b(1):\u200b\u200b113\u200b\u2013121.","DOI":"10.1515\/hsz-2020-0212"},{"key":"8702_CR17","doi-asserted-by":"publisher","first-page":"eabd3079","DOI":"10.1126\/scitranslmed.abd3079","volume":"13","author":"A Fomin","year":"2021","unstructured":"Fomin A, et al. Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations. Sci Transl Med. 2021;13:eabd3079.","journal-title":"Sci Transl Med"},{"key":"8702_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1515\/hsz-2024-0023","volume":"405","author":"R Wali","year":"2024","unstructured":"Wali R, et al. Integrated machine learning and multimodal data fusion for patho-phenotypic feature recognition in iPSC models of dilated cardiomyopathy. Biol Chem. 2024;405:427\u201339.","journal-title":"Biol Chem"},{"key":"8702_CR19","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1161\/CIRCRESAHA.122.321157","volume":"133","author":"Y Dai","year":"2023","unstructured":"Dai Y, et al. An Alternative Mechanism of Subcellular Iron Uptake Deficiency in Cardiomyocytes. Circ Res. 2023;133:e19\u201346.","journal-title":"Circ Res"},{"key":"8702_CR20","doi-asserted-by":"crossref","unstructured":"Saleem HN, et al. 3D computational modeling of defective early endosome distribution in human iPSC-based cardiomyopathy models. Cells. 2024;13.","DOI":"10.3390\/cells13110923"},{"key":"8702_CR21","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42:681\u20133.","journal-title":"Eur Heart J"},{"key":"8702_CR22","doi-asserted-by":"publisher","first-page":"E1848","DOI":"10.1073\/pnas.1200250109","volume":"109","author":"X Lian","year":"2012","unstructured":"Lian X, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109:E1848\u20131857.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8702_CR23","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nprot.2012.150","volume":"8","author":"X Lian","year":"2013","unstructured":"Lian X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt\/beta-catenin signaling under fully defined conditions. Nat Protoc. 2013;8:162\u201375.","journal-title":"Nat Protoc"},{"key":"8702_CR24","doi-asserted-by":"publisher","first-page":"255ra130","DOI":"10.1126\/scitranslmed.3009027","volume":"6","author":"AD Ebert","year":"2014","unstructured":"Ebert AD, et al. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system. Sci Transl Med. 2014;6:255ra130.","journal-title":"Sci Transl Med"},{"key":"8702_CR25","doi-asserted-by":"crossref","unstructured":"Xu H, et al. Non-negative blind deconvolution for signal processing in a CRISPR-edited iPSC-cardiomyocyte model of dilated cardiomyopathy. FEBS Lett. 2021;595(20):2544\u20132557.","DOI":"10.1002\/1873-3468.14189"},{"key":"8702_CR26","doi-asserted-by":"crossref","unstructured":"Habeck M, Saleem N, Plota D, Cheruiyot C, Kohl T, Lehnart S, Jakobs S, Ebert A. Sarcomere analysis in human cardiomyocytes by computing radial frequency spectra. bioRxiv. 2025;28(05):655290.","DOI":"10.1101\/2025.05.28.655290"},{"key":"8702_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","volume":"117","author":"D Kolijn","year":"2021","unstructured":"Kolijn D, et al. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation. Cardiovasc Res. 2021;117:495\u2013507.","journal-title":"Cardiovasc Res"},{"key":"8702_CR28","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690\u2013700.","journal-title":"Eur J Heart Fail"},{"key":"8702_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"31","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, et al. Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes. Cardiovasc Drugs Ther. 2017;31:233\u201346.","journal-title":"Cardiovasc Drugs Ther"},{"key":"8702_CR30","doi-asserted-by":"publisher","first-page":"8265","DOI":"10.1038\/s41598-025-93144-9","volume":"15","author":"O Mourad","year":"2025","unstructured":"Mourad O, Vohra S, Nunes SS. Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure. Sci Rep. 2025;15:8265.","journal-title":"Sci Rep"},{"key":"8702_CR31","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","volume":"115","author":"Z Li","year":"2019","unstructured":"Li Z, et al. Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury. Cardiovasc Res. 2019;115:1646\u201358.","journal-title":"Cardiovasc Res"},{"key":"8702_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00395-025-01136-7","volume":"120","author":"Z Li","year":"2025","unstructured":"Li Z, et al. Cardiac sodium-glucose co-transporter 1 (SGLT1) contributes to heart failure in a mouse model of diabetic cardiomyopathy. Basic Res Cardiol. 2025;120:1193\u2013207.","journal-title":"Basic Res Cardiol"},{"key":"8702_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","volume":"119","author":"S Chen","year":"2024","unstructured":"Chen S, et al. Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2. Basic Res Cardiol. 2024;119:751\u201372.","journal-title":"Basic Res Cardiol"},{"key":"8702_CR34","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","volume":"60","author":"A Baartscheer","year":"2017","unstructured":"Baartscheer A, et al. Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits. Diabetologia. 2017;60:568\u201373.","journal-title":"Diabetologia"},{"key":"8702_CR35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia. 2018;61:722\u20136.","journal-title":"Diabetologia"},{"key":"8702_CR36","doi-asserted-by":"publisher","first-page":"107424842513234","DOI":"10.1177\/10742484251323428","volume":"30","author":"S Hopkins","year":"2025","unstructured":"Hopkins S, Baqai F, Gajagowni S, Hickey G. Direct Cardiac Mechanisms of the Sodium Glucose Co-Transporter 2 Inhibitor Class. J Cardiovasc Pharmacol Ther. 2025;30:10742484251323428.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"8702_CR37","first-page":"1461","volume":"396","author":"J Hu","year":"2023","unstructured":"Hu J, et al. Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn Schmiedebergs Arch Pharmacol. 2023;396:1461\u201370.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"8702_CR38","doi-asserted-by":"publisher","first-page":"1011429","DOI":"10.3389\/fcvm.2022.1011429","volume":"9","author":"J Gao","year":"2022","unstructured":"Gao J, et al. Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. 2022;9:1011429.","journal-title":"Front Cardiovasc Med"},{"key":"8702_CR39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18:15.","journal-title":"Cardiovasc Diabetol"},{"key":"8702_CR40","doi-asserted-by":"publisher","first-page":"103010","DOI":"10.1016\/j.redox.2023.103010","volume":"69","author":"W Cai","year":"2024","unstructured":"Cai W, Chong K, Huang Y, Huang C, Yin L. Empagliflozin improves mitochondrial dysfunction in diabetic cardiomyopathy by modulating ketone body metabolism and oxidative stress. Redox Biol. 2024;69:103010.","journal-title":"Redox Biol"},{"key":"8702_CR41","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.bbamem.2013.07.011","volume":"1838","author":"V Sequeira","year":"2014","unstructured":"Sequeira V, Nijenkamp LL, Regan JA, van der Velden J. The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochim Biophys Acta. 2014;1838:700\u201322.","journal-title":"Biochim Biophys Acta"},{"key":"8702_CR42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00040.2017","volume":"99","author":"J van der Velden","year":"2019","unstructured":"van der Velden J, Stienen GJM. Cardiac Disorders and Pathophysiology of Sarcomeric Proteins. Physiol Rev. 2019;99:381\u2013426.","journal-title":"Physiol Rev"},{"key":"8702_CR43","doi-asserted-by":"crossref","unstructured":"Palmiero G, et al. Impact of SGLT2 inhibitors on heart failure: from pathophysiology to clinical effects. Int J Mol Sci. 2021;22(11):5863.","DOI":"10.3390\/ijms22115863"},{"key":"8702_CR44","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/cpt1975174400","volume":"17","author":"C Bengtsson","year":"1975","unstructured":"Bengtsson C, Johnsson G, Reg\u00e5rdh CG. Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther. 1975;17:400\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"8702_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/0091270009343932","volume":"50","author":"J Gu","year":"2010","unstructured":"Gu J, et al. Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor\u2014Neprilysin Inhibitor (ARNi). J Clin Pharmacol. 2010;50:401\u201314.","journal-title":"J Clin Pharmacol"},{"key":"8702_CR46","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3892\/br.2017.961","volume":"7","author":"H Lee","year":"2017","unstructured":"Lee H, Park JB. Evaluation of the effects of dimethylsulphoxide on morphology, cellular viability, mRNA, and protein expression of stem cells culture in growth media. Biomed Rep. 2017;7:291\u20136.","journal-title":"Biomed Rep"},{"key":"8702_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/0011-2240(73)90038-2","volume":"10","author":"AM Hak","year":"1973","unstructured":"Hak AM, Offerijns FGJ, Verheul CC. Toxic effects of DMSO on cultured beating heart cells at temperatures above zero. Cryobiology. 1973;10:244\u201350.","journal-title":"Cryobiology"},{"key":"8702_CR48","first-page":"100059","volume":"7","author":"M Meyer-Jens","year":"2024","unstructured":"Meyer-Jens M, et al. Sacubitril\/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy. J Mol Cell Cardiol Plus. 2024;7:100059.","journal-title":"J Mol Cell Cardiol Plus"},{"key":"8702_CR49","doi-asserted-by":"publisher","first-page":"5791","DOI":"10.1038\/s41598-019-42113-0","volume":"9","author":"D Pfau","year":"2019","unstructured":"Pfau D, et al. Angiotensin Receptor Neprilysin Inhibitor Attenuates Myocardial Remodeling and Improves Infarct Perfusion in Experimental Heart Failure. Sci Rep. 2019;9:5791.","journal-title":"Sci Rep"},{"key":"8702_CR50","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1007\/s00392-023-02306-0","volume":"113","author":"E Carluccio","year":"2024","unstructured":"Carluccio E, et al. Effect of sacubitril\/valsartan on cardiac remodeling compared with other renin-angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples. Clin Res Cardiol. 2024;113:856\u201365.","journal-title":"Clin Res Cardiol"},{"key":"8702_CR51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCRESAHA.118.313973","volume":"125","author":"A Ebert","year":"2019","unstructured":"Ebert A, et al. Proteasome-Dependent Regulation of Distinct Metabolic States During Long-Term Culture of Human iPSC-Derived Cardiomyocytes. Circ Res. 2019;125:90\u2013103.","journal-title":"Circ Res"},{"key":"8702_CR52","doi-asserted-by":"crossref","unstructured":"Shu YJ, et al. Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial. Chin Med J (Engl). 2021;134(16):1967\u20131976.","DOI":"10.1097\/CM9.0000000000001702"},{"key":"8702_CR53","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1161\/01.HYP.36.4.501","volume":"36","author":"MW Nickola","year":"2000","unstructured":"Nickola MW, et al. Leptin attenuates cardiac contraction in rat ventricular myocytes. Role NO Hypertension. 2000;36:501\u20135.","journal-title":"Role NO Hypertension"},{"key":"8702_CR54","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00424-004-1284-3","volume":"448","author":"FH Andrade","year":"2004","unstructured":"Andrade FH, Hatala DA, McMullen CA. Carbonic anhydrase isoform expression and functional role in rodent extraocular muscle. Pflugers Arch. 2004;448:547\u201351.","journal-title":"Pflugers Arch"},{"key":"8702_CR55","doi-asserted-by":"publisher","first-page":"H2364","DOI":"10.1152\/ajpheart.00927.2008","volume":"295","author":"JG Dobson Jr","year":"2008","unstructured":"Dobson JG Jr., Shea LG, Fenton RA. Adenosine A2A and beta-adrenergic calcium transient and contractile responses in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2008;295:H2364\u20132372.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"8702_CR56","doi-asserted-by":"publisher","first-page":"13662","DOI":"10.1073\/pnas.0805365105","volume":"105","author":"M Fluck","year":"2008","unstructured":"Fluck M, et al. Mechano-regulated tenascin-C orchestrates muscle repair. Proc Natl Acad Sci U S A. 2008;105:13662\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8702_CR57","doi-asserted-by":"publisher","first-page":"1385277","DOI":"10.3389\/fphys.2024.1385277","volume":"15","author":"F Wiedmann","year":"2024","unstructured":"Wiedmann F, et al. A porcine large animal model of radiofrequency ablation-induced left bundle branch block. Front Physiol. 2024;15:1385277.","journal-title":"Front Physiol"},{"key":"8702_CR58","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/cvr\/cvab177","volume":"118","author":"F Wiedmann","year":"2022","unstructured":"Wiedmann F, et al. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy. Cardiovasc Res. 2022;118:1728\u201341.","journal-title":"Cardiovasc Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08702-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08702-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08702-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:18:49Z","timestamp":1786691929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08702-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8702"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08702-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"W.H.Z. is founder of, equity holder in, and advisor to Repairon GmbH and myriamed GmbH. FW and CS have filed patent applications for TASK-1-based antiarrhythmic gene- and pharmacotherapy. T.M. has co-developed myrPlates (EP3464552B1) and is head of automation at myriamed GmbH. M.T. is advisor of Repairon GmbH. The other authors declare no conflict of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1056"}}